Kimia biosciences Limited has announced a board meeting scheduled for February 14, 2026, to address key corporate matters including quarterly financial results and executive leadership continuity. The pharmaceutical company informed BSE Limited about the upcoming board deliberations through a regulatory filing dated February 7, 2026.

Board Meeting Agenda

The board meeting will focus on two primary items requiring director approval:

Managing Director Re-appointment

The board will consider the re-appointment of Mr. Sameer Goel (DIN: 00161786) as Managing Director for an extended five-year period. His current tenure concludes on March 28, 2026, and the proposed re-appointment would commence immediately thereafter on March 29, 2026. The re-appointment remains subject to shareholder approval in accordance with the Companies Act, 2013 and applicable SEBI regulations.

Trading Window Restrictions

Kimia Biosciences has implemented trading window restrictions in compliance with insider trading regulations. The company closed the trading window effective January 1, 2026, for all designated persons including intermediaries and relatives. This closure applies specifically to the declaration of unaudited financial results for the quarter and nine months ended December 31, 2025.

Corporate Information

The company maintains its registered office and manufacturing works at Village Bhondsi, Damdama Lake Road, Gurugram, Haryana. Its corporate office operates from Aggarwal Millennium Tower-II in Netaji Subhash Place, Pitampura, New Delhi. Company Secretary and Compliance Officer Pallavi Garg signed the regulatory communication, ensuring compliance with listing obligations and disclosure requirements under SEBI regulations.

Kimia biosciences Limited has announced a significant leadership change with the resignation of its Chief Financial Officer (CFO) Mr. Naveen Sharma, effective February 2, 2026. The pharmaceutical company communicated this development to BSE Limited under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Resignation Details

Mr. Naveen Sharma tendered his resignation from the position of CFO and key managerial personnel on February 2, 2026, citing personal reasons for his departure. He will be relieved from his responsibilities with the close of business hours on the same date.

Regulatory Compliance

The company has fulfilled all mandatory disclosure requirements under SEBI regulations. Company Secretary and Compliance Officer Pallavi Garg (Membership No. A69848) signed the official intimation letter, ensuring compliance with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

The resignation letter was formally submitted through email communication from Mr. Sharma to the company management, requesting proper filing with the Registrar of Companies (ROC) and appropriate intimation to stock exchanges as per regulatory framework.

Company Information

Kimia Biosciences Limited operates from its registered office at Village Bhondsi, Damdama Lake Road, Gurugram, Haryana, with corporate office located in New Delhi. The company trades on BSE under scrip code 530313 with the symbol KIMIABL.

Documentation

All required annexures and supporting documents have been submitted to the stock exchange, including detailed particulars of the cessation as mandated by SEBI listing regulations. The company has maintained transparency in its disclosure process throughout this leadership transition.